Oxycodegol (also known as loxicodegol and NKTR-181) is an experimental μ-opioid receptor agonist for the treatment of pain.[1][2] It has had success for back pain as an alternative to traditional opioids,[3] which have potential for abuse. It acts more slowly on the central nervous system, reducing risk for abuse and respiratory depression.[1]
References
- ^ a b Advokat, Claire D.; Comaty, Joseph E.; Julien, Robert M. (2019). Julien's Primer of Drug Action: a comprehensive guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth Publishers. p. 565. ISBN 978-1-319-20054-1.
- ^ "NKTR-181 (Oxycodegol) Oral Tablets for. Chronic Low Back Pain". Food and Drug Administration. Archived from the original on 24 December 2020.
- ^ Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Matthew; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel; Doberstein, Stephen K; Tagliaferri, Mary; Lu, Lin; Saddhanti, Suresh; Hale, Martin (June 2019). "SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain". PAIN. 160 (6): 1374–1382. doi:10.1097/j.pain.0000000000001517. PMC 6553961. PMID 30747908.